Anavex Life Sciences Corp. (AVXL)
1.82
-0.07
(-3.70%)
USD |
NASDAQ |
Oct 02, 16:00
1.815
0.00 (0.00%)
After-Hours: 20:00
Anavex Life Sciences Net Income (Quarterly) : 7.824M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.824M |
| March 31, 2026 | -5.338M |
| December 31, 2025 | -5.681M |
| September 30, 2025 | -9.825M |
| June 30, 2025 | -13.24M |
| March 31, 2025 | -11.20M |
| December 31, 2024 | -12.11M |
| September 30, 2024 | -11.62M |
| June 30, 2024 | -12.21M |
| March 31, 2024 | -10.55M |
| December 31, 2023 | -8.622M |
| September 30, 2023 | -10.15M |
| June 30, 2023 | -11.28M |
| March 31, 2023 | -13.11M |
| December 31, 2022 | -12.97M |
| September 30, 2022 | -14.29M |
| June 30, 2022 | -12.37M |
| March 31, 2022 | -10.44M |
| December 31, 2021 | -10.88M |
| September 30, 2021 | -11.72M |
| June 30, 2021 | -10.18M |
| March 31, 2021 | -8.155M |
| December 31, 2020 | -7.855M |
| September 30, 2020 | -5.965M |
| June 30, 2020 | -6.487M |
| Date | Value |
|---|---|
| March 31, 2020 | -7.237M |
| December 31, 2019 | -6.592M |
| September 30, 2019 | -3.879M |
| June 30, 2019 | -6.522M |
| March 31, 2019 | -7.247M |
| December 31, 2018 | -6.920M |
| September 30, 2018 | -5.793M |
| June 30, 2018 | -2.849M |
| March 31, 2018 | -4.752M |
| December 31, 2017 | -4.059M |
| September 30, 2017 | -5.155M |
| June 30, 2017 | -3.610M |
| March 31, 2017 | -1.549M |
| December 31, 2016 | -3.147M |
| September 30, 2016 | -6.511M |
| June 30, 2016 | -2.240M |
| March 31, 2016 | -2.031M |
| December 31, 2015 | -3.954M |
| September 30, 2015 | -5.356M |
| June 30, 2015 | -4.240M |
| March 31, 2015 | -1.725M |
| December 31, 2014 | -0.7867M |
| September 30, 2014 | -9.699M |
| June 30, 2014 | -1.009M |
| March 31, 2014 | -1.019M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | -7.824M |
| EPS Diluted (Quarterly) | 0.0842 |
| Enterprise Value | 50.38M |
| Earnings Yield | -8.33% |
| Normalized Earnings Yield | -8.330 |